Continuous Blood Glucose Monitoring Market Report 2026

Continuous Blood Glucose Monitoring Market Overview

• Continuous Blood Glucose Monitoring market size has reached to $14.87 billion in 2025 • Expected to grow to $26.11 billion in 2030 at a compound annual growth rate (CAGR) of 12.5% • Growth Driver: Rising Diabetes Prevalence Fuels Growth In Continuous Blood Glucose Monitoring Market • Market Trend: Advancements In Next-Generation Continuous Glucose Monitoring Technologies • North America was the largest region in 2025.

What Is Covered Under Continuous Blood Glucose Monitoring Market?

Continuous Blood Glucose Monitoring (CGM) involves using a sensor under the skin to constantly track glucose levels. It provides real-time data and alerts for high or low glucose, assisting people with diabetes in managing their blood sugar levels more effectively. The main types of components in continuous blood glucose monitoring devices are insulin pumps, sensors, transmitters, and receivers. Insulin pumps are small, computerized devices designed and programmed to deliver pre-determined doses of insulin in diabetic patients at specific intervals. These devices are used by type 1 diabetic patients, type 2 diabetic patients, gestational diabetes, and critical care patients which are used by various end-users, including hospitals, homecare diagnostics, and other end users.

What Is The Continuous Blood Glucose Monitoring Market Growth Forecast?

The continuous blood glucose monitoring market size is expected to see rapid growth in the next few years. It will grow to $26.11 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to advancements in implantable and flash glucose sensors, growing homecare and remote monitoring solutions, integration with digital health platforms, increasing awareness of diabetes self-management, adoption of ai-based predictive analytics. Major trends in the forecast period include rising adoption of continuous glucose monitoring devices, integration with smartphone apps and wearables, expansion of homecare diagnostics for diabetes management, development of minimally invasive and implantable sensors, growing focus on real-time data analytics and alerts.

Global Continuous Blood Glucose Monitoring Market Segmentation

1) By Component: Insulin Pumps, Sensors, Transmitters, Receivers 2) By Application: Type 1 Diabetic Patients, Type 2 Diabetic Patients, Gestational Diabetes, Critical Care Patients 3) By End User: Hospitals, Homecare Diagnostics, Other End Users Subsegments: 1) By Insulin Pumps: Tubeless Insulin Pumps, Tubed Insulin Pumps, Patch Pumps 2) By Sensors: Continuous Glucose Monitoring Sensors, Flash Glucose Monitoring Sensors, Implantable Sensors 3) By Transmitters: Integrated Transmitters, Wireless Transmitters, Bluetooth-Enabled Transmitters 4) By Receivers: Standalone Receivers, Smartphone Apps, Integrated Devices

What Is The Driver Of The Continuous Blood Glucose Monitoring Market?

The increase in the prevalence of diabetes is expected to propel the growth of the continuous blood glucose monitoring market going forward. Diabetes is a health disease that occurs when the blood glucose levels fluctuate in the body. Blood glucose monitoring devices can aid in the detection of trends and patterns that give a better full picture of a diabetic's condition. For instance, in June 2024, according to the National Health Service (NHS), UK-based government department, among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This significant growth highlights a concerning trend in this age group. The data reflects a rapid escalation in diabetes prevalence among younger populations. Therefore, the increasing prevalence of diabetes is driving the continuous blood glucose monitoring industry growth going forward.

Key Players In The Global Continuous Blood Glucose Monitoring Market

Major companies operating in the continuous blood glucose monitoring market are F. Hoffmann-La Roche Ltd., Medtronic plc., Abbott Laboratories, GlySens Inc., Senseonics Holdings Inc., Glysure Limited, Nemaura Medical Inc., Tandem Diabetes Care Inc., Ypsomed Holding AG, Orsense Ltd., Dexcom Inc., Insulet Corporation, Medtrum Technologies Inc., Beta Bionics Inc., Bigfoot Biomedical Inc., GluSense Ltd., i-SENS Inc., Osang Healthcare Co Ltd., WaveForm Technologies, EyeSense GmbH, Calisto Medical, Biorasis, DirectSens GmbH, Ultrahuman Healthcare

Global Continuous Blood Glucose Monitoring Market Trends and Insights

Major companies operating in the Continuous Blood Glucose Monitoring (CGM) market are increasingly focusing on developing such as continuous glucose monitoring system to enhance real-time glucose tracking, improve patient convenience, and support better diabetes management outcomes. A Continuous Glucose Monitoring (CGM) system is a medical device that automatically tracks glucose levels throughout the day and night, providing real-time readings at regular intervals (typically every few minutes). For instance, in August 2025, Abbott Laboratories, a US-based healthcare company, launched the FreeStyle Libre 2 Plus system, an advanced CGM sensor that delivers continuous glucose readings every minute directly to a compatible smartphone without the need for manual scans. This sensor also includes optional low- and high-glucose alarms, 15-day wear time, and seamless integration with Abbott’s digital health ecosystem (LibreView, LibreLink Up), enabling both users and caregivers to monitor glucose trends proactively. The system is designed to improve glycemic control, reduce hypoglycemia, and provide actionable data while eliminating routine finger-sticks.

What Are Latest Mergers And Acquisitions In The Continuous Blood Glucose Monitoring Market?

In May 2023, Medtronic PLC., an Ireland-based medical device company, acquired EOFlow for an undisclosed amount. The acquisition is intended to strengthen Medtronic's diabetes product portfolio and broaden its capacity to provide comprehensive support to a larger global community of individuals managing diabetes, all within a unified Medtronic ecosystem. EOFlow Co. Ltd. Is a South Korea-based company that manufactures the insulin patch pump EOPatch.

Regional Outlook

North America was the largest region in the continuous blood glucose monitoring market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Continuous Blood Glucose Monitoring Market?

The continuous blood glucose monitoring market consists of sales of real-time continuous glucose monitoring, and intermittently scanned continuous glucose monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.